COMPASS Pathways (NASDAQ:CMPS) Earns Buy Rating from Analysts at Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a note issued to investors on Thursday,Finviz reports. The firm set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 197.30% from the company’s previous close.

CMPS has been the topic of a number of other reports. Maxim Group cut their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. HC Wainwright decreased their price target on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $27.33.

COMPASS Pathways Price Performance

Shares of CMPS opened at $3.70 on Thursday. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75. The firm has a market cap of $253.16 million, a price-to-earnings ratio of -1.68 and a beta of 2.28. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average of $4.06 and a 200-day moving average of $5.29.

Institutional Trading of COMPASS Pathways

Large investors have recently bought and sold shares of the business. Tang Capital Management LLC bought a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $3,780,000. RTW Investments LP bought a new stake in shares of COMPASS Pathways during the 4th quarter worth $11,714,000. Point72 Asset Management L.P. lifted its stake in COMPASS Pathways by 15.4% in the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company’s stock worth $257,000 after purchasing an additional 9,099 shares during the last quarter. Integral Health Asset Management LLC bought a new position in shares of COMPASS Pathways during the fourth quarter valued at about $756,000. Finally, Cubist Systematic Strategies LLC raised its stake in shares of COMPASS Pathways by 205.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company’s stock valued at $479,000 after acquiring an additional 85,213 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.